shutterstock_1569359980_sundry-photography

shutterstock_1569359980_Sundry Photography

18 May 2023Big PharmaMuireann Bolger

US govt seeks new trial in Gilead HIV drug patent case

The government lost its high stakes and unusual royalties dispute with the big pharma firm | New status report claims that the court should have allowed the jury to take four inter partes petitions into account.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Gilead and Teva prevail in $3.6bn antitrust trial

4 July 2023 Verdict confirms legality of 2014 patent settlement, dismissing allegations of anti competitive practices.

Trial set for Gilead HIV antitrust claims case

23 February 2023 Gilead, Johnson & Johnson and others will face trial in May | Class-action suit involves allegations of anticompetitive practices.

Gilead hit with antitrust suit over HIV drugs

16 January 2020 Gilead and its alleged co-conspirators Bristol-Myers Squibb, Japan Tobacco, and Johnson & Johnson have been accused of engaging in a long-running scheme to suppress competition in the market for HIV prevention therapies.

More on this story

Gilead and Teva prevail in $3.6bn antitrust trial

4 July 2023 Verdict confirms legality of 2014 patent settlement, dismissing allegations of anti competitive practices.

Trial set for Gilead HIV antitrust claims case

23 February 2023 Gilead, Johnson & Johnson and others will face trial in May | Class-action suit involves allegations of anticompetitive practices.

Gilead hit with antitrust suit over HIV drugs

16 January 2020 Gilead and its alleged co-conspirators Bristol-Myers Squibb, Japan Tobacco, and Johnson & Johnson have been accused of engaging in a long-running scheme to suppress competition in the market for HIV prevention therapies.

More on this story

Gilead and Teva prevail in $3.6bn antitrust trial

4 July 2023 Verdict confirms legality of 2014 patent settlement, dismissing allegations of anti competitive practices.

Trial set for Gilead HIV antitrust claims case

23 February 2023 Gilead, Johnson & Johnson and others will face trial in May | Class-action suit involves allegations of anticompetitive practices.

Gilead hit with antitrust suit over HIV drugs

16 January 2020 Gilead and its alleged co-conspirators Bristol-Myers Squibb, Japan Tobacco, and Johnson & Johnson have been accused of engaging in a long-running scheme to suppress competition in the market for HIV prevention therapies.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB

Lewis Roca promotes tech expert to managing partner

Panitch Schwarze brings in molecular biologist

US targets ‘product hopping’ with biologic litigation curbs

UPC confirms validity of Edwards Lifesciences heart valve tech patent

ITC concludes row over biotech lab equipment between US and German rivals

UKIPO launches ‘revolutionary’ patent filing and AI tool

USPTO clarifies AI's role in patent eligibility